Assembly Biosciences, Inc. (ASMB)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGS
34.07 USD
-0.73
(-2.098%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 34.07 |
Hot Take ↕ | Aug. 22, 2026, 3:33 a.m. EDT
The immediate outlook is driven by a powerful confluence of analyst upgrades and a specific de-risking event regarding Gilead's potential opt-in for genital herpes programs, which has sparked a sharp price recovery from the $26 lows to the current $34 level. While the statistical forecasting model offers no directional bias due to low confidence, the options market is screaming bullishness, with heavy open interest at $40 and $45 strikes indicating a collective bet on a major breakout. Fundamentally, the company remains a high-risk biotech play with negative operating margins and no dividend, but the balance sheet is surprisingly robust with massive cash reserves and negligible debt. The recent price action confirms a strong momentum shift, validating the 'strong buy' analyst consensus despite the historical volatility. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.107923 |
| MSTL | 0.115761 |
| AutoETS | 0.121900 |
| AutoTheta | 0.185258 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 3.55 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 1.06 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.769 |
| Revenue per Share | 4.574 |
| Market Cap | 693,685,504 |
| Trailing P/E | 28.16 |
| Forward P/E | -18.07 |
| Beta | 1.09 |
| Profit Margins | -0.06% |
| Website | https://www.assemblybio.com |
As of Aug. 22, 2026, 3:33 a.m. EDT: Speculators are heavily positioned for upside, evidenced by significant open interest in out-of-the-money calls (strikes $40 and $45) and a dominance of call volume over put volume across all expirations. Implied volatility is significantly elevated for puts compared to calls, suggesting a fear premium for downside protection, yet the actual positioning leans bullish. The lack of in-the-money put open interest indicates a lack of hedging against immediate collapse, while the concentration of call open interest at higher strikes suggests bets on a substantial rally rather than a modest grind higher.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.44218814 |
| Address1 | Two Tower Place |
| Address2 | 7th Floor |
| All Time High | 1,260.0 |
| All Time Low | 7.68 |
| Ask | 34.19 |
| Ask Size | 1 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 359,070 |
| Average Daily Volume3 Month | 236,535 |
| Average Volume | 236,535 |
| Average Volume10Days | 359,070 |
| Beta | 1.092 |
| Bid | 34.17 |
| Bid Size | 1 |
| Board Risk | 3 |
| Book Value | 15.398 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 5 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 34.07 |
| Current Ratio | 13.989 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 34.58 |
| Day Low | 33.29 |
| Debt To Equity | 0.769 |
| Display Name | Assembly Biosciences |
| Earnings Timestamp End | 1,754,942,400 |
| Earnings Timestamp Start | 1,754,510,400 |
| Ebitda | -8,688,000 |
| Ebitda Margins | -0.11608 |
| Enterprise To Ebitda | -43.241 |
| Enterprise To Revenue | 5.019 |
| Enterprise Value | 375,674,496 |
| Eps Current Year | 0.425 |
| Eps Forward | -1.885 |
| Eps Trailing Twelve Months | 1.21 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 27.9452 |
| Fifty Day Average Change | 6.1247997 |
| Fifty Day Average Change Percent | 0.21917179 |
| Fifty Two Week Change Percent | 44.218815 |
| Fifty Two Week High | 39.71 |
| Fifty Two Week High Change | -5.6399994 |
| Fifty Two Week High Change Percent | -0.1420297 |
| Fifty Two Week Low | 20.23 |
| Fifty Two Week Low Change | 13.84 |
| Fifty Two Week Low Change Percent | 0.6841325 |
| Fifty Two Week Range | 20.23 - 39.71 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,292,596,200,000 |
| Float Shares | 9,173,670 |
| Forward Eps | -1.885 |
| Forward P E | -18.07427 |
| Free Cashflow | -27,865,750 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 73 |
| Fullday Change | -0.73 |
| Fullday Change Percent | -2.0977 |
| Fullday Price | 34.07 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.14952 |
| Gross Profits | 11,191,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.27656 |
| Held Percent Institutions | 0.69352996 |
| Implied Shares Outstanding | 20,360,596 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,707,696,000 |
| Last Split Factor | 1:12 |
| Long Business Summary | Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California. |
| Long Name | Assembly Biosciences, Inc. |
| Market | us_market |
| Market Cap | 693,685,504 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_99715344 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -42,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 709,037,395 |
| Number Of Analyst Opinions | 4 |
| Open | 34.58 |
| Operating Cashflow | -38,481,000 |
| Operating Margins | -0.47435 |
| Overall Risk | 3 |
| Payout Ratio | 0.0 |
| Phone | 833 509 4583 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 34.07 |
| Post Market Time | 1,787,958,940 |
| Previous Close | 34.8 |
| Price Eps Current Year | 80.1647 |
| Price Hint | 2 |
| Price To Book | 2.212625 |
| Price To Sales Trailing12 Months | 9.268294 |
| Profit Margins | -0.00056 |
| Quick Ratio | 13.789 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.73 |
| Regular Market Change Percent | -2.0977 |
| Regular Market Day High | 34.58 |
| Regular Market Day Low | 33.29 |
| Regular Market Day Range | 33.29 - 34.58 |
| Regular Market Open | 34.58 |
| Regular Market Previous Close | 34.8 |
| Regular Market Price | 34.07 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 250,017 |
| Return On Assets | -0.026719999 |
| Return On Equity | -0.00026 |
| Revenue Growth | 0.389 |
| Revenue Per Share | 4.574 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 2 |
| Shares Outstanding | 20,360,596 |
| Shares Percent Shares Out | 0.1137 |
| Shares Short | 2,314,029 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 2,312,058 |
| Short Name | Assembly Biosciences, Inc. |
| Short Percent Of Float | 0.1513 |
| Short Ratio | 12.76 |
| Source Interval | 15 |
| State | CA |
| Symbol | ASMB |
| Target High Price | 62.0 |
| Target Low Price | 43.0 |
| Target Mean Price | 50.0 |
| Target Median Price | 47.5 |
| Total Cash | 320,360,992 |
| Total Cash Per Share | 15.734 |
| Total Debt | 2,350,000 |
| Total Revenue | 74,845,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 1.21 |
| Trailing P E | 28.157024 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 29.2944 |
| Two Hundred Day Average Change | 4.7756004 |
| Two Hundred Day Average Change Percent | 0.16302094 |
| Type Disp | Equity |
| Volume | 250,017 |
| Website | https://www.assemblybio.com |
| Zip | 94,080 |